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The author is an independent consultant ethicist in Victoria, Australia
1. The Problem
There has been a gradual but major change in oral contraception. The drive to
reduce metabolic assault and unwanted side-effects has resulted in a trend toward
formulations which are less contraceptive and more likely to be abortifacient.
This has a broad range of moral consequences.
There is not one formulation of the contraceptive-abortifacient pill but many
varieties. In general, there are three actions involved: the effect on the cervix, on
ovulation and on the lining of the uterus.
The estrogen content is significant in suppressing ovulation. The lower the
estrogen dose, the greater the likelihood that ovulation will not be suppressed. In
the latter case the cervical and endometrial factors are more significant. In the
various formulations it is not known how often that both ovulation is not
suppressed and the cervical factor fails to block the passage of sperm and so
allows fertilization followed by an endometrial effect causing loss of the zygote.
However it is likely that that is sometimes the result of taking oral contraception
and it is more likely in the circumstances of the newer formulations with their
much lower estrogen content and reduced effect on ovulation. The likely induced
loss rate of zygotes, though low, is of serious moral significance because it is
human life that is at risk.
The progesterone-only formulations are more likely to have this unfortunate
abortifacient result than the combined estrogen-progestogen formulations.
The "contraceptive pill" (meaning either the combined estrogen and
progestogen preparations or the progestogen only preparations) ought not be
regarded as contraceptive only. There is a significant chance of abortifacient
effect which increases as the estrogen content diminishes. The increased
likelihood of the various formulations being abortifacient changes the moral
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evaluation of material cooperation by health professionals in regard to
contraception. The grave matter of justice and respect for nascent human life

arises.
There is a need for clear teaching on contraceptive-abortifacients and the deceit
involved, not only in order to address the matter of respect for human life but also
the matter of the rights of women to know what they are doing to their own bodies
and to the lives for whom their bodies are rendered hostile. Such a statement might
also address the moral conclusions that flow from that information in regard to the
practice of contraception and abortifacience and the issue of cooperation.
Also to be considered are new birth control developments other than the
estrogen-progestogen pill. The new preparations are nearly all primarily
abortifacient although they are usually trialled, approved and/or marketed
misleadingly as "contraceptive".
2. The Distinction Between Contraception and Abortifacience

For the purposes of this analysis which is concerned ultimately with some moral
questions, the terms "abortifacient" and "contraceptive" are defined in the
following way:
A contraceptive effect occurs when the natural process of human generation
originating in the marital act is prevented, by some form of deliberate intervention
in the human body or in the act itself, from resulting in fertilization of an ovum by a
sperm.
An abortifacient effect occurs when intervention takes place of a kind which
would be likely, if fertilization were to have occurred, to destroy the human
zygote, embryo or fetus, to prevent its implantation, or to cause an implanted
embryo or fetus to miscarry. The human zygote is the cell formed by the fusion of
the two gametes ("Zygotum est cellula ona afusione duorum gametum"J).
There is a distinct difference between the moral significance of a contraceptive
effect and of an abortifacient effect. The fruit of human generation, from the first
moment of its existence, that is to say from the moment the zygote is formed,
demands the unconditional respect that is morally due to the human being in his
bodily and spiritual totality. ("Quare fructus generationis humanae, inde a primo
temporis momento quo exsistere incipit. hoc est a momento quo formatio zygoti
inchoatur, absolutam illam exgit observantiam, quae ex lege morali homini debetur
quoad totam suam rationem corpora/em atque spiritualem "2)
There are at least twenty-four different formulations of the estrogenprogestogen oral contraceptive in approved use in Australia3• They do not all have
the same pharmacological action. It is not merely a question of being stronger or
weaker doses of the same hormones, but different preparations with different
effects.
To clarify the matter, this section differentiates between each of the types of the
pill in approved use in Australia and gives an account of the effects of each type in
regard to the mechanism by which they prevent the development of pregnancy, so
far as the specific pharmacological actions are known. In addition, some details of
6
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new formulations which are currently being experimentally tried in Australia, but
are not yet approved for general use, are also included. Finally, an opinion is
offered in regard to moral issues arising from the blurring of the distinction
between contraception and abortion that has occurred through the gradual
development of contraceptives toward being more abortifacient than contraceptive.
3. Combined Pills

These are pills which have a combination of both estrogen and progestogen4.
The estrogen in all the approved formulations available in Australia is
ethinylestradiol with the daily dosage varying between 30 - 50 mcg 5• The
progestogen content however comes in several formulations: Levonorgestrel
(150-250 mcg), Norethisterone (500-1000mcg) Ethynodiol diacetate (500lOOOmcg) and Desogestrel (l50mcg)6. The formulation and the dosage are both
significant in relation to the action of the pills in regard to which of the three
actions - the suppression of ovulation, the disruption of cervical mucus, or
changes to the endometrium (causing loss of the zygote) - are likely to be factors
preventing fertilization and/or the development of a pregnancy.? Further, the
response to these agents varies from woman to woman and between cycles. As the
woman's own hormonal levels fluctuate from cycle to cycle and different women
have different hormonal levels, the action of these agents on the ovaries, cervix and
endometrium varies.s
The effect of the formulations is on the hypothalamus and/or the pituitary gland
in the brain which produce the hormones which affect the reproductive cycle9.
Some of the formulations work to suppress Follicle Stimulating Hormone (FSH)
and Luteinizing Hormone (LH), some suppress only FSH production, and some
simply disturb the FSH and LH cycle so that instead of the LH surge happening
following a period of sustained FSH, there may be several LH pulses which do not
coincide with follicle maturation. Some suppress only LH. Some formulations
may simply disrupt the coincidence of the receptiveness of the endometrium to
implantation, cervical mucus sperm penetrability and ovulation so that while these
events' occur they do not happen with a timing that allows both fertilization and
implantation to occur.IO
Generally, if the formulation being used has a high estrogen content, then the
likelihood is that ovulation will be suppressed and the matter of an abortifacient effect
on the endometrium would not arise.11 In the formulations with a low estrogen
content, ovulation would be less likely to be suppressed and the actions of the
progestogen on the cervix and the endometrium become more significantl2.
Generally, the higher and the more prolonged the dose of progestogen, the greater the
disruption to the cervial mucus and the lower the chance of fertilization occurring and
hence the lower the chance of an abortifacient effectl3.
The type of progestogen formulation being used is also relevant Some have a
slower more sustained absorption than others. Some are rapidly absorbed. Some
have a shorter half-life than others. These differences are significant A sustained level
of progestogen throughout the day is probably necessary to maintain disruption of
the cervical mucus, thus maintaining a contraceptive effect. Whether it is necessary
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for it to be sustained to maintain the effect on the endometrium or whether the
endometrium would be sufficiently disrupted by daily peaks of progesterone is not
clear. Peaks and troughs in the progesterone levels may cause the breakthrough
bleeding seen in some women using the low dose oral contraceptive pill, indicating
that the endometrium is disturbed 14. In that case the abortifacient effect on the
endometrium, rather than the contraceptive effect achieved in the cervix, is more
likely in formulations that do not provide a sustained level of the hormones
throughout the day. An additional factor is that it appears that the ratio of&tradiol
to Progesterone is significant in relation to the effect on the endometrium IS.
In the event of low estrogen levels, ovulation occurring and unsustained
progestogen levels, it is not clear from the literature which is the more likely to
function adequately, the cervical mucus or the endometrium. Hence it is not
possible to say definitely that there are circumstances with the combined pills in
which the sperm penetrates the ovum and fertilization occurs, but the zygote is lost
because of the damage to the endometrium. It may be the case that the disruption
to cervical function is always relatively greater than the damage to the
endometrium. However, it should be assumed that any damage to the
endometrium is likely to increase the risk of zygote loss. The combined pill
certainly causes atrophic changes to the endometrium which then becomes an
unreceptive environment to the zygote. Second, there is a pregnancy rate in the
actual clinical use of the combined pill indicating that the cervical effect is not
always sufficient. For those reasons the possibility that the combined pill in some
circumstances allows fertilization to occur while increasing the likelihood of
implantation failure cannot be considered as improbable. That probability
increases in the combined pills using lower estrogen doses.
So far this discussion has presumed strict compliance in users in both taking the
pill each day and taking it at the same time of day. Of course this often does not
happen. Most of the pregnancies associated with pill usage are attributed to user
error rather than method error. It can only be a matter of speculation as to which of
the organs is the first to function when a pill is missed or delayed, the ovaries, the
cervix or the endometrium. Hence it is not known how many missed pills actually
result in fertilization and subsequent failure to implant. At a guess it d~ seem
probable that the endometrium may be slower to return to function than the cervix
and hence the abortifacient effect may be more likely}6
Similarly, many drug interactions which reduce the efficacy of oral
contraceptives resulting in pregnancy are known l7• It is not known how often drug
interaction would be sufficient to allow ovulation and sperm penetration, but
would not be sufficient to prevent damage to the endometrium and hence an
abortifacient effect 18•
There is some indication that there may be a prolonged effect of the oral
contraceptives on both the endometrium and the cervix after a woman has ceased
taking the pill. There may well be a greater likelihood of miscarriage in that period
also as a result of some chromosomal abnormalities. 19 Professor Jerome Lejeune
drew attention to the greater incidence of chromosomal abnormalities resulting in
miscarriage, and thought that there was a greater incidence of Trisomy 21 (Down
Syndrome) after the use of hormonal contraception. 20 It is worth noting that the
8

Linacre Quarterly

consumer advice from the manufacturers cautions that pregnancy should be
avoided in the first three months after ceasing the combined oral contraceptive.
4. Progestogen-Only Pills (the mini-pill)

The progestogen-only pill is recommended for women who experience side
effects with the combined pills and for women who are lactating in whom the
estrogen component of the combined pills would interfere with lactation21 .
The formulations used in the progestogen-only pill (mini-pill) in Australia are
Levonorgestrel (3Omcg') and Norethisterone (35Omcg)ll. The mini-pill not only
does not include estrogen, it also has a significantly lower progestogen dose than
the combined pill. For that reason it has far fewer side effects but a higher
pregnancy rate (3 per hundred women years23). In particular, the more dramatic
pharmacological effects and probable harmful side effects associated with estrogen
do not occur24 . The scientific data suggests that the progestogen-only pill does not
prevent ovulation in more than half of the women who use it. The range would
seem to vary between 67% and 81 % of cases in which ovulation failed to be
suppressed when the progesterone-only pill was used in women who had been
normally ovulating25.
The progestogen-only pill therefore depends largely on the other two factors:
the disruption of the cervical mucus function 26 and the changes to the lining of the
uterus27. It is not known precisely which is more likely.
Significantly, the effect on the endometrium differs between the different
progestogen preparations28. What significance this has for the sustained effect of
the formulations and whether the endometrial factor is likely to be more or less
significant than the cervical factor has not been established29•
It should be borne in mind that our interest in which factor is significant is not
reflected in the published research priorities. A computer search of the literature
yielded no recent study that aimed to find out whether the progestogen-only pill
was abortifacient or contraceptive. The priorities in the literature are efficacy in
terms of preventing the development of pregnancy and on the side-effects for
women. The concentration at the moment is on pill usage in relation to cancer,
cardio-vascular disease, drug interaction, metabolic disorders and some other
diseases. Some progestogen-only formulations may be administered as an intranasal spray rather than as a pill. The pharmacological effects would be much the
same.30
5. Triphasic and Biphasic Pills

These are combined estrogen and progesterone formulations, but with the
dosages of each varying through the month. Their purpose is to mimic more
closely the normal cycle. With the ordinary combined pills, the same combined
dosage is taken for 21 days of the cycle with inert tablets being taken for the rest
(approx 7 dayS)31. A menstrual bleed occurs, but because the endometrial
development has been so altered it is often a much lighter, less significant bleed32 .
The triphasic pills generally have a consistent level of estrogen at a relatively low
dose, but they vary in the amount of progestogen. Some (such as Triphasil,
Triquilar, Trifeme and Logynon ED) use Levonorgestrel with 50mcg in the first
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six days, 75 mcg in the next five days and 125 mcg in the next 10 days. Thus the
progestogen level gradually increases. Others (such as Synphasic) use
Norethisterone with 500meg for the first seven days, lOOOmcg for the next nine
days and 500 meg for the next five days33.
With the lower dose of estrogen, it is more likely that ovulation is not always
suppressed or disrupted and the cervical and endometrial factors become
significant. A recent review of seven of the low dose combined pills showed that on
ultrasound examination and serum hormone estimations ovarian suppression
occurred in only 50% of cycles.34 The efficacy in terms of preventing pregnancy
remained high with tablet related pregnancy, as distinct from patient error
pregnancy, remaining at less than one per hundred women years. 3S In those
circumstances the endometrial and cervical factors are essential for the prevention
of the development of pregnancy.
The different levels of progestogen used at the different stages of the cycle are
also significant in regard to which effect is more dominant, the contraceptive effect
on the cervix or the abortifacient effect on the endometrium.36 A constant level of
progrestogen would be needed to maintain the cervical factor. In the formulations
in which the level of progestogen wanes significantly during the day, it would be
much more likely that the endometrial (abortifacient) factor would be preventing
pregnancy.
The biphasic pills (such as biphasil and sequilar ED) use a constant 50mcg of
ethinyloestradiol but vary the levonorgestrel from 50mcg in the first eleven days
and 125mcg in the next ten days3? Hence, the estrogen level is high and most likely
prevents ovulation. The cervical mucus and endometrial effects of the
progestogen, although a back-up in case ovulation suppression fails, are thus
probably not so significant in those formulations.
6. Tricyclic Pills

Athletes competing at sporting events, women marrying and wanting the
wedding night free of menstruation, women undergoing academic examination
and women simply not wanting the inconvenience of monthly cycles may choose
to extend the twenty-one days of pill taking. Tricyclic pills extend the menstrual
cycle to three months.
The combined pill mainly suppresses ovulation and also has the back-up effects
on the endometrium and the cervix. The woman experiences something like
menstruation only after she stops taking the pill. The choice to use a standard
twenty-one days of pill-taking followed by seven days of an inert pill establishes a
regular twenty-eight day cycle. The manufacturers choose to do it that way,
mimicking the normal menstrual cycle. However, shorter or longer periods may
be chosen by varying the period that the combined pill is taken. 38 Presumably the
three actions of the combined pill remain the same in these long cycles but whether
the actions on each of the target organs are more or less severe is seemingly not
known. 7. Post-CoitaI Oral Contraceptive Use

In Australia, the practice of using combined the estrogen-progestogen pill in
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high dosage as a morning-after pill is becoming more common. One of the high
dose pills is used. Two pills are taken immediately and two more are taken twelve
hours later. The result is a very high estrogen and progestogen peak followed soon
after by a heavy bleed. The probable mechanism is abortifacient. It is possible that
ovulation is suppressed depending on when the medication is taken in the cycle.
The stage of the cycle and the time between intercourse and taking the pills would
obviously be crucial in determining whether it is the contraceptive effect that
works prior to the abortifacient effect and hence prevents fertilization 39.
General practitioners report that the demand for the morning-after pill has
increased markedly in the last few years, probably as a result of condom
promotion in relation to sexually transmissible diseases. It is common for teenagers
to ask for the morning-after pill. It appears that, in the knowledge that the
morning-after pill will resolve the problem, they may not take other precautions.
Often they are accompanied to the doctor by their mothers! More women seemed
to be depending on condoms in conjunction with the morning-after pill in the
event of condom breakage or leakage. In actual human use, as distinct from
laboratory testing, breakage rates in condoms that meet WHO laboratory test
standards are between 7-13%40. Hence the demand for so-called "post-coital
contraception", that is, abortifacients, is significant.
8. Fonnulations Other than Estrogen-Progestogen Pills

The major trend in fertility control seems to be toward the development of
abortifacients. The new methods are sought as replacements for the intra-uterine
device and the contraceptive pill. Intra-uterine devices are out of favour because of
their reputed association with pelvic inflammatory disease. The contraceptive pill
is contra-indicated now for women who smoke and there are reservations about its
use in women over thirty-five. In addition, the tedium of a daily dose and disquiet
about its side-effects have led to the search for alternatives to the contraceptive pill.
Some attempts have been made to improve barrier methods but the major
candidates for the future of medical control of fertility seem to be the antiprogesterones, anti-estrogens, vaccines, inhibin, synthetic GnRH (Gonadotrophin
Releasing Hormones), and monthly injections or implants.
9. Antiprogesterones

The so-called "abortion pill"41 RU486 (mifepristone) has been the centre of
some controversy. Apart from the fact that RU486 causes abortions, pro-lifers
have been concerned that the pill could be used on a regular basis; that it would be
self-administered and would thus allow abortions to be achieved easily in the
privacy and secrecy ofthe woman's home; and that the language used to describe it
hides the fact that it is abortifacient. The new word "contragestive" is frequently
used42 .
RU486 is being heavily promoted by the population control and pro-abortion
lobbies and it is likely to gain widespread acceptance for use after pregnancy has
been confirmed, as an alternative to surgical abortion, and possibly earlier as an
immediate post-coital treatment. RU486 is now being trialled in Australia both in
low dose as an immediate post-coital treatment, and later when the pregnancy is
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known to have been established43 • The trial in Australia is a part of a WHO
international multi-centre trial.
Some prcrabortionists have supported the agent as a much easier way of procuring
an abortion than the surgical procedures involving curettage or vacuum aspiration.44 •
Some have claimed that it could be used without a pregnancy test when pregnancy is
a possibility and menses are delayed. It has been argued that this would avoid the
problems of guilt, and other psychological sequelae in relation to abortion: the
woman would not know whether she had been pregnant.
RU486 is a progesterone antagonist. It acts to inhibit the function of progesterone
at the receptor level in the endometrium and other organs that respond to
progesterone. In plain language that means that RU486 makes progesterone
ineffective. Progesterone is essential for maintaining the lining of the uterus during
pregnancy. Within a few days of administering RU486 after pregnancy has been
established, the lining of the uterus sheds, taking with it the embryo or fetus if the
woman is pregnant's.
Administered immediately after coitus before pregnancy can be confirmed it
would also seem to prevent nidation but the mechanism is uncertain. In the latter
case, according to the plain language statements46 of the Australian trials,
menstruation is usually delayed47. If administered very early after pregnancy has been
established, the woman would experience an early abortion as a very heavy period48 •
RU486, used on its own, after pregnancy has been established, procures an early
abortion in approximately 85% of cases49. However if used in conjunction with other
agents the success rate may be as high as 95-100%50. RU486 can also be used
effectively in the secondSI and third trimestersS2• If the current trial using RU486
immediately after coitus is successful, then is likely to be used frequently as a back-up
following barrier method failureS 3• At first it was claimed that RU486 might be used
to regularize cycles and prevent pregnancyS4, but uncertainty about the prolonged
effects and dosages needed have led to the conclusion that this would not be
appropriate5s. In addition the menses which follow the taking of RU486 are heavy
and prolongedS6• The agent is thus not likely to be particularly appealing as a
once-a-month "contraceptive".
One of the problems inhibiting the use of RU486 as a "menstrual regulator" is that
its effect is to block the function of progesterone. The rise in progesterone, on which
so much depends, does not occur until the latter part of the cycle. This meant that, at
first, it was held that if used too early in the cycle, the effectiveness of RU486 would
be reduced. It was thought not to be effective in the absence ofluteal phase levels of
progesteroneS7• The current WHO trial which Australia is participating in will prove
or disprove that hypothesis. If the WHO trial is successful, RU486 might even gain
approval as a self-administered home abortion pill. However the research and the
manufacturers currently hold that it should only be used under close medical
supervisionS8. The major reason for this is that there is usually heavy, prolonged
bleeding which may endanger the woman's healths9. Follow-up treatments such as
blood transfusion and curettage may be indicated in a small percentage of cru;es6O.
The action of RU486 in inhibiting the effect of progesterone on the lining of the
uterus is not the only direct effect. Some studies have shown that RU486 directly
inhibits placental hormone secretion, having a direct effect on the embry061. Thus
12
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RU486 not only brings about an abortion by affecting the lining of the uterus, it
may also directly damage the embryo. The latter would be particularly relevant in
the event that a woman chose not to have curettage after RU486 failed to procure
an abortion. A complex range oflegal and ethical issues would arise in that event.
If a woman had been ambivalent in the first instance, one could well imagine her
deciding not to go further in the event of RU486 failure. Her rights and the medical
and pharmaceutical liabilities would provoke conflict in such circumstances. The
damage done to the embryo, and subsequently the child born at a later stage,
would be an issue which the courts and the community would have to heed.
The medical literature also contains the information that while the hormonal
functions of the woman return to normal after RU486 has been used, there may be
lasting effects on the tissues of the uterus and cervix. One study shows that cell
dynamics which depend on a continuity of progresterone will be irreversibly
disrupted62 • The long term effects and the potential for serious adverse reactions
are not yet known. The literature claims that it is safe, but only time will tell. The
effects of hormonal treatments of this kind can be insidious and may only appear
much later as was the case with the early high dose contraceptive pill, with some
fertility drugs, and with some morning sickness therapies.
RU486 can readily cross the blood-follicle barrier of human pre-ovulatory
follicles. RU486 and its metabolites have been found in the egg-follicles in the
ovaries of women undergoing sterilization to whom RU486 had been
administered thirty-four hours earlier63• A question must therefore arise about the
potential for damage to the ovaries and the egg follicles and the risk to any children
subsequently conceived by a woman who has undergone RU486 therapy.
RU486 does have some uses other than inducing abortion. Research has been
done on it as a therapy following fetal death. Research has also been done on
RU486 as an aid to ripening the cervix thus facilitating surgical abortion 64 • The
agent may also be of therapeutic value in the treatment of breast cancer65.
There is a very real danger that RU486 might be approved for prescription in
Australia. Probably the conditions for its approved use would require that it be
administered under close medical supervision. However, medical practitioners
who are passionately in favour of private abortions might well interpret "close
medical supervision" liberally and, at risk to their patients, prescribe RU486 in
such a way as to allow it to be used as a home abortion pill. Once in the hands of
unqualified personnel RU486 might then be adapted for regular use after menses
delay in spite of that use being contra-indicated.

10. Anti-estrogens
A new development not yet reported to have been applied to humans is the
development of anti-estrogens. A substance currently called CDRI-85/287 has
been developed which interacts with the estrogen receptors thus blocking estrogen
function in the same way that RU486 blocks progestrone function 66• Estrogen is
thought to have an essential role to play in the healthy functions of the cervix, the
cervical mucus and sperm transport, in maintaining the corpus luteum, in ovum
transport, and in the functions of the endometrium67 • An anti-estrogen thus would
be likely to disrupt healthy reproductive function. CDRI-85/287 has been shown
February, 1995
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to affect implantation by causing changes to the rat uterus68 . There are other
similar developments such as the anti-estrogens ICI-182780 and nylestriol which
have also been shown to inhibit implantation69 •
11. Contraceptive and Abortifacient Vaccines

The immune system may be utilized in a number of ways in order to render a
couple infertile. In layperson's terms, the immune system works by identifying a
foreign body, then attacking it. Immunity develops normally by exposure to
foreign bodies and the immune system learning to recognize them. Thus, for
instance, a virus may infect a person, the immune system eventually recognizes it,
targets it and then destroys it. In that process the immune system will have
recorded the event and from then on retains the means of rapidly recognizing the
virus. Future exposure to the virus results in an immediate attack response thus
preventing the development of infection and illness.
Two ways in which the contraceptive vaccines are likely to function are by
producing a foreign body recognition of a man's sperm by his own immune
system, or by producing a foreign body recognition of a man's sperm by his wife's
immune system. The fertilizing capacity of the sperm is affected by the immune
system and the system's response to the sperm may occur at many sites. 70 For
instance the anti-bodies may affect the sperm in the cervical mucus or at the site of
sperm being absorbed in the ovum's zona pellucida.7 1 A further contraceptive
possibility arises in relation to producing an immune response to ova72.
The new ethical issues which arise in relation to the developments of
contraceptive vaccines are to do with the risks for harm. The men and women who
are subject to the experiments run the risk of developing an auto-immune disease.
That is to say, the antibodies created may not be specific enough in targeting sperm
or ova, and other tissues may be attacked. However, if animal studies show that
these risks are minimal then the question of risk taking is only a matter of gaining
informed consent to experiments. A much more complex issue would arise in
relation to the risk of conception occuring and a child developing who had been
damaged by experiments with vaccines against the sperm or ova from which he or
she was conceived.
A further use of the immune system, and a much more likely use, is the
development of antibodies which inactivate key reproductive hormones necessary
for the maintenance of a pregnancy. Anti-bodies to human chorionic
gonadotrophin have been developed73. The latter has already been achieved in
primates and is now being tried in women74 . Such vaccines are abortifacient in that
they act against the placenta and hence destroy the pregnancy.
A major problem in relation to the abortifacient vaccine is that it is often
described as contraceptive when there is little doubt that it is abortifacient. The
effect is on the hormone produced by the chorion and the chorion does not exist
prior to the formation of an embryo. The chorionic cells are not established until
implantation is under way7S.
12. Inhibin

Inhibin is a naturally-occurring hormone identified by a Melbourne group of
14
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scientists. It is thought to have a function as a messenger informing the
hypothalamus in the brain about the status of development of ova or sperm. It may
have a use in suppressing LH and FSH production thus potentially preventing
ovulation.76

13. Implants and Monthly Contraceptives
Contraceptives that are injectable once a month and contraceptive implants
ha ve been developed.
Narp/ant is a subdermal slow release levonorgestrel implant which acts as a long
term progestogen "contraceptive". A major function it has is to alter the
endometrium thus preventing implantation 77 , but it also alters the cervical mucus
and sometimes prevents ovulation 78 •
eyclajem and Mesigyna (containing medroxyprogesterone acetate) are once-amonth injectable "contraceptives" releasing both estrogen and progestogen 79.
From the literature it is not clear what levels of the two hormones are maintained
throughout the month, and that makes it difficult to assess what is the predominant
action: suppression of ovulation, changes to the cervical mucus or endometrial
changes. Moral assessment might assume a similar action as that of the combined
pill - probable suppression of ovulation and cervical mucus changes inhibiting
fertilization, with the endometrial changes providing abortifacient back-up.
However, the monthly injection is likely to provide a diminishing level of the
hormones as the month progreses. It is probable that it depends more on being
abortifacient than the daily oral contraceptives.
It is thought that formulations containing medroxyprogesterone acetate may
cause very severe lasting damage to the endometrium, even a condition called
Asherman's syndrome when the woman may ovulate without menstruation.
Asherman's syndrome can also occur after a radical destruction of the
endometrium in the performance of a surgical abortion, and it can also occur as a
congenital under-development of the uterus.80

14. GnRH
Gonadotrophin releasing hormone (GnRH) has an effect on the pituitary gland,
the ovary and the testis. In men it inhibits the formation of sperm. GnRH is
normally produced by the hypothalamus and works on the pituitary gland to
trigger the production ofFSH and LH. The synthetic variety is more potent8l , One
established effect of using a synthetic GnRH is in fact to block the action of
estradiol 82 . The latter may have some use in altering cervical mucus function,
suppressing ovulation and changing the endometrium.

15. Hormone Releasing IUDs
A further development is that of intra-uterine contraceptive devices (IUDs)
which release progesterone. The effect would probably be to enhance the effect of
the IUD on the lining of the uterus causing changes that prevent implantation. 83

16. Some Moral Consequences of the Trend Toward Abortifacients
16.1 The Objective Problem
The development of the moral tradition in regard to contraception has
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presumed that contraception was, in fact, contraception. It now appears that many
if not all of the pharmacological contraceptives are at least in part abortifacient,
and the newer preparations under development tend to be entirely abortifacient,
notwithstanding that they are promoted as contraceptives.
This raises serious questions not only for the moral tradition but also for Church
discipline. The Code of Canon law holds that a person who actually procures an
abortion incurs a {atae sententiae excommunication (Canon 1398) and abortion is
defined by the Pontifical Commission for the Authentic Interpretation of Canon
Law as any method used to terminate a human life from the moment of
conception until birth.
Objectively, and assuming that one should always favor human life, the
abortifacient component of oral contraceptives should result in them being
regarded as abortifacient and assessed that way. That is, assessed as involving not
only the wrong of contraception but the even more serious wrong of procuring an
abortion. In the higher-dose combined pills that risk is relatively small but not
assuredly so small that it is morally insignificant. Further it is a matter of risking
human life which makes even a relatively small risk a serious matter.
The moral assessment of the use of oral contraceptives for other medical
purposes such as the management of hormonal imbalance, dysmenorrhoea and
acne, must also change now that it is clear that the formulations are at least in part
abortifacient. It is a question both of justice and proportionality. Significantly
risking the life of a new human being is a disproportionate consequence of such
treatments in a woman who is sexually active. The use of the estrogenprogesterone contraceptive formulations for non-contraceptive purposes should
be restricted to women who are not sexually active or are known to be otherwise
incapable of conceiving. This would not, of course, preclude the use of hormone
supplements for the purposes of treating infertility where the aim is to restore
reproductive health so as to achieve pregnancy, provided that they were not used
in doses that diminished the chances of a zygote implanting.
Pastorally there are several matters to address in response to the information
that oral contraceptives are at least partly abortifacient. The problem IS
experienced differently by:

*
*
*

women and their partners using contraceptive-abortifacient formulations,
the doctors who prescribe the formulations,
the pharmacists filling prescriptions,

*
*

the manufacturers and researchers, and

*

the Church

the legislators and public policy-makers.

16.2 Women Taking "Contraceptives"
A major factor in the moral question in regard to women using pharmaceutical
contraceptives is whether the abortifacient effect can be considered to be intended
by them. Advice about the effects of oral contraceptives are provided to women
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with packets of the pill. The high dose combined pills which are most likely to
suppress ovulation and are thus least likely to have an abortifacient effect because
fertilization would not usually occur, still carry a message to users, such as the
following:
The ho rmonal components [ . . . the preparation is named ... ) inhibit ovulation by
suppressing gonadotrophin release. Secondary mechanisms which may contribute to the
effecti veness of[ ... the preparation .. . Jas a contraceptive include changes in the cervical
mucus (which increase the difficulty of sperm penetration) and changes in the
endometrium (which reduce the likelihood of implantation).

Users are therefore informed of the anti-implantation effect but they may not
understand that that is, in reality, an abortifacient effect. This does have a bearing
on whether the pill is taken in good faith (in respect to taking an abortifacient) as a
contraceptive and not as an abortifacient.
Often, anti-implantation effects would seem not to be regarded as morally the
same as abortion. The Congregation for the Doctrine of the Faith's teaching in
198784 that the zygote (the cell formed by the fusion of the gametes) is to be given
the respect due to the human person is not universally held even amongst
theologians and that dissension, uncertainty or ignorance affects laypeople.
Given that there is loss or possible loss of life involved in taking the oral
contraceptive, women should be warned that that is the case and the moral
conclusions drawn as a matter of pastoral guidance.
Further, this may be treated as a matter of proportionality in that the intention
of an informed woman (that is, one who knows of the possibility of an
abortifacient effect) in taking an oral contraceptive may be to take a contraceptive
and the abortifacient effect may simply be thought of as an unfortunate side effect.
However, it is a question of loss of life and the proportionality conditions of the
doctrine of double effect would have a bearing on the moral assessment even
though the intention may be judged to be good in respect of not directly choosing
abortion (but not, of course, in regard to contraception). There is a grave danger
that the induced loss of early human life is being treated with indifference. In fact it
is a matter of the utmost gravity.
It has been argued by the Bishops of England and Wales that such a risk could
be legitimately taken in the circumstances of rape85. That is to say, the Bishops
accepted that contraception might be attempted after rape, and in an otherwise
detailed treatment of the issue, left unanswered the question of the moral
acceptability of the fact, acknowledged by them, that such contraceptive attempts
might also be abortifacient in the circumstances of blind administration in which it
was not known whether ovulation and possible fertilization had occurred.
This matter needs clarification. What is appropriate management in the
circumstances of rape? Is the self-defence argument in favor of attempting postcoital contraception acceptable in the extreme case of rape when there are good
grounds for believing that ovulation has not yet occurred? If so, is it permissible to
attempt contraception in circumstances in which fertilization may not be
prevented or may have already occurred and an abortifacient effect may be the
result?
A certain amount of risk-taking is obviously permissible in life. Every time we
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travel by automobile we risk human lives. The question is one of the level of risk. If
those risks were increased, at some point they would become unconscionable.
That is to say they become disproportionate. The same must be said of the risk of a
contraceptive-abortifacient in the circumstances of rape. At some point the risk of
losing a life rather than preventing the generation of a life becomes
disproportionate.
It is important to stress that this question only arises in the circumstances of rape.
One could not consider such ajustification in the ordinary circumstances of freel y
chosen acts, first because of the wrong of contraception, and second because
contraception is not necessary for family planning. The ovulation awareness
methods provide a viable and satisfactory ( not to mention healthier and morally
acceptable) alternative.
The significance of this discussion however is that the increasing likelihood of
the contraceptive formulations being in fact abortifacient further vitiates such acts,
adding an even more serious dimension - significant risk to human life.

16.3 Prescribers
Although women using the contraceptive-abortifacient formulations may be
ignorant of the abortifacient risks, the same should not be the case for prescribers.
Women using contraceptives might simply trust the advice given that what has
been prescribed is in fact a contraceptive. But a medical practitioner should know
more about the preparations.
It is sometimes argued that the role of a medical practitioner in prescribing
contraceptives is merely material co-operation and that the decision to contraceive
is that ofthe patient rather than the practitioner. To the contrary, the reality is that
the medical practitioner is a party not merely materially to the evil, but to the
decision itself. It is the practitioner who puts the options to the woman. It is the
practitioner who writes the prescription instructing the pharmacist. It is therefore a
matter of conscience for the practitioner in regard to the wrong of contraception.
Now that it is clear that the contraceptive formulations carry a significant risk of
loss of life, the matter of prescribing them assumes an even more serious dimension
for the prescribers. They not only participate formally in contraception, they also
share direct responsibility for risking human life.
There is a climate of wreckless indifference in regard to human life, particularly
nascent human life, which medical practitioners should seek to resist and to
challenge,

16.4 Hospitals
Much of what is said about prescribers also applies to hospitals. It really
depends on the nature of the hospital's co-operation, the legal authority it has
over prescribers within the hospital, and the extent to which such matters can
be made the subject of formal policy and decisions by the hospital.
It is worth noting that in 1971 the United States Catholic Conference drew
a distinction in this respect, reportedly based on advice from the
Congregation for the Doctrine of the Faith, between abortion and
sterilization . The USCC held that it was sometimes permissible
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for hospitals to remotely materially (but not formally) cooperate in sterilization
but never in abortion. 86
The difference of course is that abortion involves matters of justice in regard to
the unborn child. The same matters now are involved in the trend toward
abortifacients in the pharmacological methods of birth control.
Catholic hospitals exist to give practical healing witness to the teachings of
Christ and of His Church. They, more than any other institutions, must have
hospital policies and staff development policies which are in accord with an ethos
of respect for human life and dignity. This matter of the developments in regard to
contraceptive-abortifacients provides a serious cultural challenge to the reason for
the existence of Catholic health care institutions, particularly those providing
services in obstetrics and gynecology.

16.5 Pharmacists
The situation of pharmacists has always been a complex one. They are
professionally trained and registered and expected to give advice about their
preparations. However, in Australia they cannot generate or modify prescriptions
without medical authorization. Contraceptive formulations are only available by
medical prescription. It is an offence to sell or supply a prescription medication
without a doctor's prescription. Pharmacists may, of course, be self-employed or
be employed by hospitals or companies and that does affect the degree of freedom
to refuse to fill a doctor's prescription on conscientious grounds.
Generally it has been accepted, as a matter of theological opinion, that
pharmacists materially, but not formally, co-operate when supplying contraceptives
on a doctor's prescription. They are not a formal part of the evil and the oral
contraceptives sometimes have medical uses other than contraception. However
the principles of co-operation do require that the co-operation not be an injustice.
The fact that the contraceptive formulations are significantly abortifacient changes
the moral assessment. There is a grave matter of injustice to the human being, at
the zygote stage of his or her development, in supplying formulations which put
the life at risk.
For that reason, this review of the medical literature and the conclusion reached
that oral contraceptives at least risk being abortifacient has led me to change the
view I previously held in regard to advising pharmacists. I am now inclined to the
view that pharmacists should not fill prescriptions for oral contraceptiveabortifacients to customers who may be sexually active.

16.6 Manufacturers and Researchers
The trend toward developing so-called "contraceptive" formulations that tend
to be entirely or in part abortifacient is most unfortunate.
Those who conscientiously are engaged in the pharmaceutical industry, in
marketing, research, development or production, have moral obligations to ensure
that their product is a good product. That is, that it is unlikely to cause harm and is
good for human persons. Manufacturers cannot be held to be morally responsible
for all the ways in which a product may be applied. But they are responsible for
identifying its recommended applications and warning about potential harm or misuse.
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That a pharmaceutical may cause loss of a human life at any stage of
development ought not be hidden behind euphemism or misleading terms. Such
medications should contain clear warning to that effect. The worst part of the
current dilemma is the fact that abortifacients have been accepted readily because
they have been marketed as contraceptives only, something other than what they
are.
Researchers also co-operate in the development of such products and they owe
a duty of care to the community in regard to the contribution their efforts make to
the society. The contemporary concentration in contraceptive research on
developing abortifacients and the failure to distinguish between contraceptive and
abortifacient effects is a serious wrong.

16.7 Public Policy
The safety of human life is an essential concern of the State in its role as
protector of the common good. The development, production, marketing, supply,
prescription and use of abortifacients is a matter which public authorities have an
obligation to seek to control.
It is part of the duty of the public authority to ensure that the civil law is regulated
according to the fundamental norms of the moral law in matters concerning human rights,
human life and the institution ofthe family. Politicians must commit themselves, through
their interventions upon public opinion, to securing in society the widest possible
consensus on such essential points and to consolidating this consensus wherever it risks
being weakened or is in danger of collapse.87

16.8 The Church
A major problem in regard to the development of contraceptives toward being
abortifacient is the manner in which abortifacients have come to be accepted as
contraceptives. The source of the problem is medical indifference to the
destruction of nascent human life. From that indifference flows a failure to
communicate to women the real nature of the treatments and hence an ignorance
on the part of both women and the general community.
As a defender of human life and human dignity it is of grave importance that
once having recognized that source of the problem, the teaching resources of the
Church be employed to address the deficiency. More than anything this is a matter
of insisting that women are given full information about the effects of the
contraceptives.
The Church is often accused of being embryo-centric to the exclusion of the
rights bf women and their free choice. Here, however, it is those who would
threaten the lives of the innocent who are denying free choice to women by
denying them relevant information needed to make decisions about family
planning. This is not only injustice to the child in the womb, but an injustice to
women.
There is a need for clear teaching on abortifacients and the deceit involved,not
only as a matter of respect for human life but also as a matter of the rights of
women to know what they are doing to their own bodies and to the lives for whom
their bodies are rendered hostile without the women's knowledge.
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17. Contraceptive Failure

Contraceptive failure with the oral contraceptives occurs both as a result of
method failure and as a result of user error and interaction with other medications.
From a pro-life perspective, the nature ofthe support and advice given to women
in such instances is of great importance. This is particularly so when the use of a
reasonably reliable method of contraception fails and the woman has no prior
expectation of pregnancy.
The method-related failures of oral contraceptives are given thus:
The pregnancy rates in women using conventional combination oral contraceptives
(containing 35 micrograms or more of ethinyloestradiol or 50 micrograms or more
mestranol) is generally reported as less than I pregnancy per 100 woman-years of use.
Slightly higher rates (somewhat more than I pregnancy per 100 woman-years of use) are
reported for some combination products containing 35 micrograms or less of
ethinyloestradiol, and rates of the order of 3 pregnancies per 100 woman years are
reported for the progestogen-only oral contraceptives.88

If you take into account that many woman become sexually active in their teens,
their actual childbearing period is to be limited to two or three live births, and their
naturally fertile life will extend over thirty years, then most women will wish to
avoid pregnancy for twenty to twenty-five years. The chance of having an
unexpected pregnancy at some time during their fertile years if they depend on the
pill during the times that they do not want to be pregnant is thus 20-25% with the
conventional preparations, more than 20-25% with the low dose combined pill
and 60-75% with the progestogen-only pill, and that is without allowing for user
failure such as missing pills, taking them at a different time of day, taking them
with agents which have a known drug interaction with oral contraceptives, or
having a stomach upset.
The failure rate thus accounts for a significant proportion of unplanned
pregnancies. Such pregnancies come as a complete surprise, particularly if they are
entirely method-related. Many women think that the pill makes them immune to
pregnancy, hence when it occurs in a woman taking the pill, it can be devastating.
From a realistic pro-life perspective, permanent sterilization apart, willingness
to engage in sexual intercourse should be premised upon a willingness to accept the
possibility of pregnancy and the birth of a child. A pro-life view should thus link
sexual intercourse with a willingness to form a family. That view is not shared by
the Family Planning Associations.
The chances of a pregnancy can be greatly reduced by oral contraceptives. The
chances can also be limited to an equivalent extent by the timing of sexual
intercourse so that it does not coincide with the fertile stage of the cycle. Possible
fertile times can be identified readily by the presence of cervical mucus observed at
the vulva on that day or the preceding three days. The World Health Organization
figures 89 indicate that the Billings Ovulation Method of observing mucus changes
is more reliable than the mini-pill and about as reliable as the combined pills. The
observation of the temperature rise that follows ovulation is also an indication of
the fertile period having passed. Those natural methods can also be assisted, for
women who find observation of the signs of fertility difficult, by the use of
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hormonal testing which is now available in a Do-It-Yourself Kit.
The disadvantage of the abstinence methods is that they do involve days of
abstinence. The major advantages are that they do not involve the health risks and
unpleasant side-effects of the oral contraceptives, do not carry the abortifacient
risks of the oral contraceptives, foster a co-operative relationship between spouses
in which responsibility for controlling fertility is shared, increase awareness of the
changes in the woman's body, provide early warning of a variety of medical
conditions, and provide information which assists couples who have difficulty
conceiving.
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